human elf4 cdna (OriGene)
OriGene is a verified supplier 
OriGene manufactures this product 
93
Structured Review
OriGene
human elf4 cdna
Human Elf4 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+elf4+cdna/pmc12645360-84-1-13?v=OriGene
Average 93 stars, based on 1 article reviews
Human Elf4 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+elf4+cdna/pmc12645360-84-1-13?v=OriGene
Average 93 stars, based on 1 article reviews
human elf4 cdna - by Bioz Stars,
2026-08
93/100 stars
Images
1) Product Images from "ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer"
Article Title: ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer
Journal: Journal of Cellular Physiology
doi: 10.1002/jcp.70113
Figure Legend Snippet: ELF4 is highly expressed in EC and is associated with poor prognosis. (A) mRNA expression of ELF4 in endometrioid tumors, papillary serous cancers, and normal endometrial tissues from GEO dataset GSE17025 . Data presented as mean ± SD. The p values were adjusted by Tukey's method between each group. (B) Spearman correlation analysis of ELF4 expression and histological grade in TCGA Uterine Corpus Endometrial Carcinoma (UCEC) database, analyzed using TISIDB. (C) IHC analysis of ELF4 protein expression across histological grades in slides of an EC tissue microarray. Left panel: Representative images of ELF4 staining intensity in EC specimens, with insets showing magnified view of indicated area. Right panel: Quantification of ELF4 expression in human EC specimens using HistoQuest software, presented as mean ± SD; * p < 0.05 by Tukey's multiple comparisons test. (D, E) Kaplan‐Meier curves of UCEC patients from TCGA database, stratified by median ELF4 mRNA expression levels: (D) Overall survival (OS) and (E) Recurrence‐free survival (RFS). Significance determined by log‐rank test for both.
Techniques Used: Expressing, Microarray, Staining, Software
Figure Legend Snippet: Knockdown of ELF4 suppresses cell proliferation and reduces CDK6 protein levels in EC cells. (A–C) Colony formation assay in (A) AN3CA, (B) HEC‐1A, and (C) EMC6 cells transduced with shLacZ or ELF4‐specific short hairpin RNAs (shRNAs), followed by crystal violet staining and colony counting. (D) Cell cycle analysis by propidium iodide (PI) staining and flow cytometry in cells transduced with shLacZ or ELF4‐specific shRNAs. Data are presented as mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001 versus shLacZ‐transduced cells, unpaired Student's t test. (E–G) Western blot analysis of ELF4 and CDK6 protein levels in (E) AN3CA, (F) HEC‐1A, and (G) EMC6 cells transduced with shLacZ or ELF4‐specific shRNAs, using GAPDH as loading control. Band intensities were quantified and expressed as mean ± SEM; *** p < 0.001 versus shLacZ, unpaired Student's t test.
Techniques Used: Knockdown, Colony Assay, Transduction, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Control
Figure Legend Snippet: ELF4 transcriptionally regulates CDK6 expression in EC cells. (A) Spearman's correlation analysis of ELF4 and CDK6 expression in UCEC patients, performed using GEPIA2. (B) Relative mRNA levels of ELF4 and CDK6 in AN3CA, HEC‐1A, and EMC6 cells transfected with control (siCtrl) or ELF4‐specific small interfering RNAs (siELF4), measured by SYBR‐Green‐based quantitative reverse transcription PCR (qRT‐PCR). Data are fold changes (mean ± SD) versus siCtrl; * p < 0.05; ** p < 0.01; *** p < 0.001, unpaired Student's t ‐test. (C, D) Western blot analysis of CDK6, ELF4, and GAPDH expression in AN3CA, HEC‐1A, and EMC6 cells transfected with siCtrl or siELF4, using GAPDH as loading control. Band intensities quantified by ImageJ were presented as mean ± SEM (D); ** p < 0.01; *** p < 0.001 versus siCtrl, Student's t test. (E) Upper panel: CDK6 promoter with putative ELF4 binding motifs (red bars). Lower panel: Luciferase reporter assay in AN3CA, HEC‐1A, and EMC6 cells co‐transfected with pGL3‐CDK6 promoter constructs and pCMV‐NCV or ELF4‐Flag plasmids. Data were presented as fold changes (mean ± SD) versus pCMV‐NCV; ** p < 0.01, unpaired Student's t ‐test. (F) Chromatin immunoprecipitation (ChIP) assay in AN3CA and HEC‐1A cells using anti‐ELF4 antibody or IgG control, followed by qPCR detection of the ELF4 binding fragments within CDK6 promoter. Data presented as mean ± SD; * p < 0.05 versus anti‐IgG, unpaired Student's t ‐test. Western blot analysis of CDK6, ELF4‐Flag, and GAPDH expression in 293 T cells (G) or HEC‐1A cells (H) transfected with pCMV‐NCV or ELF4‐Flag vectors, using GAPDH as loading control. Band intensities quantified by ImageJ are mean ± SEM. ** p < 0.01 versus pCMV‐NCV, unpaired Student's t test (G). * p < 0.05 versus pLVX‐puro, unpaired Student's t ‐test (H).
Techniques Used: Expressing, Transfection, Control, SYBR Green Assay, Reverse Transcription, Quantitative RT-PCR, Western Blot, Binding Assay, Luciferase, Reporter Assay, Construct, Chromatin Immunoprecipitation
Figure Legend Snippet: Knockdown of ELF4 reduces β‐catenin and c‐MYC protein levels and inhibits tumorsphere formation. Western blot analysis of β‐catenin, c‐MYC, and GAPDH expression in (A) AN3CA, (B) HEC‐1A, and (C) EMC6 cells transduced with shLacZ or ELF4‐specific short hairpin RNAs (shELF#1 or shELF4#2), using GAPDH as loading control. Band intensities are mean ± SEM; *** p < 0.001 versus shLacZ, unpaired Student's t test. Tumorsphere formation assay in cells transduced with shLacZ or ELF4‐specific shRNAs (shELF#1 or shELF4#2), assessed by (D) imaging and (E) counting tumorspheres after 7‐10 days using an inverted light microscope. Data are presented as mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001 versus shLacZ‐transduced cells, unpaired Student's t ‐test.
Techniques Used: Knockdown, Western Blot, Expressing, Transduction, Control, Tube Formation Assay, Imaging, Light Microscopy
Figure Legend Snippet: Inhibition of CDK6 blocks self‐renewal activity in EC. (A) MTT assay of cell viability in AN3CA, HEC‐1A, and EMC6 cells transfected with control (siCtrl) or CDK6‐specific small interfering RNAs (siCDK6), plated at 3000 cells/well in 96‐well plates. Data are mean ± SD; * p < 0.05; *** p < 0.001 versus siCtrl, unpaired Student's t ‐test. Tumorsphere formation assay in AN3CA, HEC‐1A, and EMC6 cells transfected with siCtrl or siCDK6, assessed by (B) imaging and (C) counting tumorspheres after 7–10 days using an inverted light microscope. Data are presented as mean ± SD; * p < 0.05; *** p < 0.001 versus siCtrl, unpaired Student's t ‐test. (D) Western blot analysis of CDK6, OCT4, NANOG, c‐MYC, and GAPDH expression in AN3CA, HEC‐1A, and EMC6 cells transfected with siCtrl or siCDK6, using GAPDH as loading control. Relative band intensities versus siCtrl were indicated. (E) MTT assay of cell viability in AN3CA, HEC‐1A, EMC4, EMC5, and EMC6 cells seeded at 3000 cells/well in 96‐well plates and treated with increasing Palbociclib doses. Data are presented as relative viability (mean ± SD) versus vehicle controls. Tumorsphere formation assay in AN3CA, HEC‐1A, and EMC6 cells seeded at 1 × 10⁴ cells/well in ultra‐low attachment 6‐well plates, treated with Palbociclib or vehicle for 7–10 days, assessed by (F) imaging and (G) counting tumorspheres using an inverted light microscope. Scale bar: 100 μm. Data presented as are mean ± SD; *** p < 0.001 versus vehicle, unpaired Student's t ‐test. (H, I) Western blot analysis of NANOG, OCT4, c‐MYC, and GAPDH expression in AN3CA, HEC‐1A, and EMC6 cells treated with Palbociclib or vehicle, using GAPDH as loading control. Relative band intensities versus vehicle from three independent repeats were shown in (I). * p < 0.05; ** p < 0.01; *** p < 0.001 vs vehicle control (Ctrl), unpaired Student's t ‐test. (J, K, L) HEC‐1A cells were transduced with lentiviruses carrying shLacZ or shELF4 sequences followed by transfecting with vectors of empty (NCV) or myc‐tagged CDK6 cDNA (CDK6‐myc). The expressions of myc‐tagged CDK6 and ELF4 were confirmed by western blot (J). Cell viability at 72 h or 96 h post‐transduction was determined by MTT (K). ** p < 0.01; *** p < 0.001; # p < 0.05; ### p < 0.001. CSC activity was examined by tumorsphere assay (L).
Techniques Used: Inhibition, Activity Assay, MTT Assay, Transfection, Control, Tube Formation Assay, Imaging, Light Microscopy, Western Blot, Expressing, Transduction
Figure Legend Snippet: TRIB3 cooperates with ELF4 to regulate CDK6 expression in EC. (A) Heatmap of CDK6 expression in TRIB3‐knocked‐down HEC‐1A cells, generated using ClustVis from two independent replicates. (B) Spearman's correlation analysis of TRIB3 and CDK6 expression in UCEC patients of TCGA database, performed using GEPIA2. (C) Relative mRNA levels of TRIB3 and CDK6 in AN3CA, HEC‐1A, and EMC6 cells transduced with shLacZ or TRIB3‐specific short hairpin RNAs (shTRIB3#1 or shTRIB3#2), measured by SYBR‐Green‐based qRT‐PCR. Data are presented as fold changes (mean ± SD) versus shLacZ; ** p < 0.01; *** p < 0.001. (D) Western blot analysis of CDK6, TRIB3, and GAPDH expression in AN3CA, HEC‐1A, and EMC6 cells transduced with shLacZ or TRIB3‐specific shRNAs, using GAPDH as loading control. Relative band intensities versus shLacZ were indicated. (E) Spearman's correlation analysis of TRIB3/ELF4 and CDK6 expression in UCEC patients of TCGA database, performed using GEPIA2. (F) ChIP‐qPCR assay assessing TRIB3 binding to putative ELF4 binding elements on the CDK6 promoter in AN3CA and HEC‐1A cells, using anti‐TRIB3 antibody or normal rabbit IgG as control. Data are presented as mean ± SD; * p < 0.05; ** p < 0.01, *** p < 0.001 versus anti‐IgG, unpaired Student's t ‐test. (G) 293 T cells were transfected with the indicated plasmids for 48 h and total cell lysates were extracted as input. After IP with anti‐HA or control mouse IgG (mIG) antibodies, the pull down proteins were subjected to western blot for HA tagged TRIB3 fragments or flag tagged ELF4. (H, I) 293 T cells were transfected with indicated plasmids for 48 h and total cell lysates were extracted and subjected to western blot for analyzing the levels of flag tagged ELF4, HA tagged TRIB3 fragments, and CDK6 (H). GAPDH was used as a protein loading control. The quantitative data of band intensities were quantified by ImageJ three independent experiment repeats are presented as mean ± SEM (I). ** p < 0.01; *** p < 0.001; # p < 0.05; ## p < 0.01 by unpaired Student's t ‐test. n.s., not significant.
Techniques Used: Expressing, Generated, Transduction, SYBR Green Assay, Quantitative RT-PCR, Western Blot, Control, ChIP-qPCR, Binding Assay, Transfection
Figure Legend Snippet: Combination of CDK6 and β‐catenin inhibition enhances EC‐CSC targeting effects. (A) Cells were treated with palbociclib and/or CCT031374 (CCT) as indicated. After 72 h, cell viability was measured by MTT assay. ** p < 0.01; *** p < 0.001, compared to cells without CCT treatment. ### p < 0.001. Cells were treated with 5 μM palbociclib, 5 μM CCT, or a combination of both drugs at 5 μM, followed by tumorsphere cultivation. Tumorspheres were imaged and counted using inverted microscopy on Day 7 (B); quantification data are shown in (C). * p < 0.05; ** p < 0.01; *** p < 0.001, compared to nontreated cells. # p < 0.05; ## p < 0.01; ### p < 0.001. (D, E, F, G) Cells were treated with 5 μM palbociclib, 5 μM CCT, or both drugs in combination for 48 h. Protein expression levels of OCT4 and c‐MYC (D, E), or ELF4, TRIB3, and β‐catenin (F, G), were analyzed by western blot. Quantitative data of band intensities in (E) and (G) resulted from three independent experimental repeats are quantified by ImageJ and are presented as mean ± SEM. represent results. * p < 0.05; ** p < 0.01; *** p < 0.001, compared to non‐treated cells. # p < 0.05; ## p < 0.01; ### p < 0.001. n.s., not significant.
Techniques Used: Inhibition, MTT Assay, Inverted Microscopy, Expressing, Western Blot
Figure Legend Snippet: ELF4 and CDK6 expressions show a positive correlation in EC specimens. (A) Representative IHC images of ELF4, TRIB3, and CDK6 staining intensities in slides of an EC tissue microarray. (B) Pearson's correlation analysis of ELF4 and TRIB3 expressions in EC specimens. (C) Pearson's correlation analysis of ELF4 and CDK6 expression in EC specimens. (D) Pearson's correlation analysis of TRIB3 and CDK6 expression in EC specimens. (E) Overall survival (OS) curves for UCEC patients in the TCGA database, stratified by co‐expression of ELF4, TRIB3, and CDK6 mRNA (upper tertile cutoff), generated using the Kaplan‐Meier plotter tool. Significance assessed by log‐rank test.
Techniques Used: Staining, Microarray, Expressing, Generated